Towards a Smoke-free Hong Kong: Final Action Needed

Regulations by 2FIRSTS.ai
Feb.02.2024
Towards a Smoke-free Hong Kong: Final Action Needed
Hong Kong should take final action on tobacco by banning its use, according to the Smoking and Health Committee.

According to a report on Hong Kong Radio website on February 1st, the Hong Kong Smoking and Health Committee has stated that if the government is to achieve its target of a smoking rate of 7.8% by 2025, it should take ultimate action against tobacco. The definition of ultimate action is to cease the commercial use of tobacco and nicotine. This ultimate action has already been implemented in countries such as the UK, New Zealand, and Malaysia.

 

Henry Tong, chairman of the committee, stated, "Our committee's recommendation is that by 2030, the smoking rate in Hong Kong should be reduced to 5%. From then on, the government can take steps towards achieving a completely smoke-free Hong Kong.

 

In a radio program called "Hong Kong Today" on Hong Kong Radio, Tong expressed his intention to increase tobacco taxes in the upcoming budget. He stated that "currently, tobacco taxes in Hong Kong account for about 64% of the retail price, which is insufficient. The World Health Organization recommends that tobacco taxes should account for 75% of the retail price of tobacco products. Therefore, we propose that the Financial Secretary increase tobacco taxes to at least 75% of the retail price of cigarettes. This would help reduce the smoking rate in Hong Kong from approximately 9.5% to 8.8%.

 

Other measures proposed by Tong include expanding smoke-free areas to reduce secondhand smoke, banning flavors that appeal to women and young smokers, such as menthol, and increasing the warning labels on cigarette packaging from the current 85% to 100%. He also called for stricter enforcement by law enforcement agencies to combat cigarette smuggling.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

STMA Issues Trial Credit Management Rules for E-Cigarette Manufacturers and Wholesalers
STMA Issues Trial Credit Management Rules for E-Cigarette Manufacturers and Wholesalers
Mar.26 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar’s Ministry of Health said it has received cabinet authorization to enforce an e-cigarette ban under the Essential Supplies and Services Law, listing prohibited acts including the import, export, sale, possession, storage, carrying, distribution and use of vaping products.
Feb.26 by 2FIRSTS.ai
Imperial Brands Expands Blu Fruit-Flavour Offerings Following Consumer Preference Data
Imperial Brands Expands Blu Fruit-Flavour Offerings Following Consumer Preference Data
Imperial Brands has announced the launch of a new Sour Berry flavour for its Blu vape range. The product will launch across retail this month, with both the Blu bar kit and Blu pod pack carrying a recommended retail price of GBP 5.99 (approximately USD 7.79, based on 1 GBP ≈ 1.30 USD).
Apr.03 by 2FIRSTS.ai
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai